This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arena: 'Marginal' Obesity Drug Now Unsafe?

SAN DIEGO ( TheStreet) -- The efficacy of Arena Pharmaceuticals' (ARNA - Get Report) weight-loss drug lorcaserin is still marginal but now the drug may also be unsafe.

That's my read of a new lorcaserin study in diabetes patients released by Arena Tuesday morning. U.S. regulators rejected lorcaserin in October, calling the drug's ability to help obese patients lose weight "marginal." Nothing in the just-announced "BLOOM-DM" data is going to change that perception.

Alarmingly, however, lorcaserin's relatively clean heart safety profile from prior phase III studies takes a hit in the BLOOM-DM study, with almost six times as many lorcaserin patients reporting new cases of heart valve damage compared to patients treated with placebo after one year.

Arena shares closed Monday at $1.53.

The BLOOM-DM study enrolled just over 600 patients who were obese and suffered from Type 2 diabetes. Patients were treated with either lorcaserin twice daily or a placebo and followed for 52 weeks.

Lorcaserin patients reported a mean weight loss of 4.5% compared to 1.5% weight loss for placebo patients. The 3% weight loss (placebo adjusted) for lorcaserin is slightly worse than the 3.1% and 3.6% mean weight loss results (also placebo adjusted) from the two prior phase III studies. The result also falls below one of two minimum efficacy standards for weight-loss drugs set by FDA.

Diabetics have a hard time losing weight, so efficacy results from the Bloom DM study were not expected to be as robust.

After one year, 37.5% of lorcaserin patients lost at least 5% of their body weight compared to 16.1% of placebo-treated patients. This result satisfies one of the FDA's efficacy's standards for new weight-loss drugs.

Lorcaserin didn't do much to help patients resolve other diabetes-related health issues either. Lorcaserin-treated patients were able to reduce blood glucose levels by 0.5% (placebo adjusted) but changes in fasting insulin, triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, and systolic and diastolic blood pressure were not statistically significant.

On the safety side of the BLOOM-DM study, 2.5% of lorcaserin-treated patients reported new cases of valvulopathy, or heart-valve problems, compared to 1.9% of placebo patients after six months of treatment.

Measured at one year, 2.9% of lorcaserin patients reported new valvulopathy but the rate for placebo-treated patients fell to 0.5%.

Arena said the BLOOM-DM study was not designed to "detect meaningful differences in the incidence of valvulopathy." The company did not, however, offer an explanation for why the rates of valvulopathy were numerically higher in the lorcaserin-treated patients.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARNA $4.06 0.37%
OREX $3.96 -1.10%
VVUS $1.43 -5.30%
AAPL $118.40 -2.40%
FB $94.13 0.13%

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs